Study of Oral Treatments for Hepatitis C
Public ClinicalTrials.gov record NCT02786537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.
Study identification
- NCT ID
- NCT02786537
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 1,275 participants
Conditions and interventions
Conditions
Interventions
- SOF/LDV (sofosbuvir/ledipasvir) Drug
- PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) Drug
- EBR/GZR (elbasvir/grazoprevir) Drug
- Ribavirin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2016 (Type not available)
- Primary completion
- Jun 13, 2019 (Actual)
- Completion
- Sep 2, 2020 (Actual)
- Last update posted
- Dec 6, 2021
2016 – 2020
United States locations
- U.S. sites
- 38
- U.S. states
- 23
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Liver Wellness Center | Little Rock | Arkansas | 72205 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| UCSD Medical Center | San Diego | California | 92103 | — |
| UCSF/Zuckerberg San Francisco General Hospital and Trauma Center | San Francisco | California | 94110 | — |
| Univ of California, San Francisco | San Francisco | California | 94143 | — |
| Yale University Digestive Diseases | New Haven | Connecticut | 06520 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Howard University | Washington D.C. | District of Columbia | 20060 | — |
| University of Florida | Gainesville | Florida | 32610-0272 | — |
| University of Florida, Jacksonville | Jacksonville | Florida | 32209 | — |
| University of Miami/Schiff Center for Liver Diseases | Miami | Florida | 33136 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Internal Medicine Associates of Wellstar Atlanta Medical Center | Atlanta | Georgia | 30312 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Northwestern University | Chicago | Illinois | 60647 | — |
| Indiana University Medical Center | Indianapolis | Indiana | 46202 | — |
| John Hopkins University | Lutherville | Maryland | 21093 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| GI Associates & Endoscopy Center | Flowood | Mississippi | 39232 | — |
| Saint Louis University | St Louis | Missouri | 63104 | — |
| University of Nebraska Medical Ctr | Omaha | Nebraska | 68198 | — |
| Southwest CARE Center | Santa Fe | New Mexico | 87505 | — |
| Mt. Sinai Beth Israel | New York | New York | 10003 | — |
| New York Langone Medical Center | New York | New York | 10016 | — |
| Weill Cornell Medical College | New York | New York | 10021 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Mountain View Medical Center | Valatie | New York | 12184 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University of Cincinnati | Cincinnati | Ohio | 45267 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Research Specialist of Texas | Houston | Texas | 77030 | — |
| Bon Secours St. Mary 's Hospital of Richmond (Liver Institute of Virginia) | Richmond | Virginia | 23226 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23284 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| University of Washington | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02786537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2021 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02786537 live on ClinicalTrials.gov.